€165M
The financing from Sofinnova Partners and Old College Capital will support the launch of precision fibrosis therapeutics.
Forth Therapeutics
Forth Therapeutics develops next-generation precision treatments for fibrosis.
€165MTotal raised
Forth Therapeutics is a biotechnology company advancing precision medicines for fibrosis across multiple organ systems. Operating from Edinburgh and Cambridge, the business builds on academic research from the University of Edinburgh.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Current assets
Members only
Cash, assets and headcount from Forth Therapeutics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
Alex Leech
CEO
Alex serves as chief executive of Forth Therapeutics and partner at Sofinnova Partners, alongside chairmanships at Ensocell Therapeutics and Sevenless Therapeutics. His background includes roles as entrepreneur in residence at Bicycle Therapeutics and chair at 2N Pharma.
LinkedIn
Neil Henderson
Chair of Tissue Repair and Regeneration at the University of Edinburgh
Neil is the founder and chief scientific officer of Forth Therapeutics, alongside his academic roles as chair of tissue repair and regeneration at the University of Edinburgh and a Wellcome Trust senior fellow in clinical science.
LinkedIn